Drug Profile
NP 003
Alternative Names: NP-003Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Neuraltus Pharmaceuticals
- Developer Neuraltus Pharmaceuticals; The Hospital for Sick Children
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lysosomal storage diseases; Parkinson's disease
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO)
- 28 Jan 2018 No recent reports of development identified for preclinical development in Lysosomal storage diseases in Canada (PO)
- 15 Jan 2016 NP 003 is still in preclinical trials for Lysosomal storage diseases in Canada